| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NPY2R |
| Uniprot No | P49146 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-381aa |
| 氨基酸序列 | MGPIGAEADENQTVEEMKVEQYGPQTTPRGELVPDPEPELIDSTKLIEVQ VVLILAYCSIILLGVIGNSLVIHVVIKFKSMRTVTNFFIANLAVADLLVN TLCLPFTLTYTLMGEWKMGPVLCHLVPYAQGLAVQVSTITLTVIALDRHR CIVYHLESKISKRISFLIIGLAWGISALLASPLAIFREYSLIEIIPDFEI VACTEKWPGEEKSIYGTVYSLSSLLILYVLPLGIISFSYTRIWSKLKNHV SPGAANDHYHQRRQKTTKMLVCVVVVFAVSWLPLHAFQLAVDIDSQVLDL KEYKLIFTVFHIIAMCSTFANPLLYGWMNSNYRKAFLSAFRCEQRLDAIH SEVSVTFKAKKNLEVRKNSGPNDSFTEATNV |
| 预测分子量 | 69 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NPY2R重组蛋白的参考文献示例(部分为虚构文献，仅供参考方向)：
---
1. **"Functional expression and characterization of the human neuropeptide Y Y2 receptor in baculovirus-infected insect cells"**
*作者：Müller A, et al. (2003)*
**摘要**：研究利用杆状病毒-昆虫细胞系统成功表达人源NPY2R重组蛋白，通过放射性配体结合实验验证其与神经肽Y的高亲和力，并证明其与G蛋白偶联的信号传导功能。
2. **"Cryo-EM structure of the neuropeptide Y Y2 receptor bound to a peptide agonist"**
*作者：Yang D, et al. (2022)*
**摘要**：通过冷冻电镜技术解析NPY2R与激动剂PYY3-36复合物的三维结构，揭示受体激活的构象变化及配体结合口袋的关键残基，为靶向药物设计提供结构基础。
3. **"Development of a mammalian cell-based NPY2R purification system for pharmacological screening"**
*作者：Brown KE, et al. (2016)*
**摘要**：优化哺乳动物细胞表达体系(如HEK293)生产重组NPY2R，建立高效纯化流程，并应用于高通量筛选拮抗剂，发现潜在抗肥胖候选分子。
4. **"Neuropeptide Y Y2 receptor dimerization studied by FRET using fluorescent protein-tagged recombinant receptors"**
*作者：Li J, et al. (2019)*
**摘要**：通过荧光标记的NPY2R重组蛋白，利用荧光共振能量转移(FRET)技术证明受体在细胞膜上的二聚化现象，探讨其对信号转导的调控机制。
---
**注**：以上文献标题及内容为示例性质，实际研究需以真实数据库(如PubMed、Web of Science)检索为准。建议使用关键词“NPY2R recombinant”“Y2 receptor expression”或结合具体研究方向筛选文献。
**Background of NPY2R Recombinant Protein**
Neuropeptide Y receptor type 2 (NPY2R) is a G protein-coupled receptor (GPCR) that binds neuropeptide Y (NPY), a widely distributed neurotransmitter involved in regulating physiological processes such as appetite, energy homeostasis, stress responses, and circadian rhythms. NPY2R is one of four NPY receptor subtypes (Y1. Y2. Y4. Y5) and is primarily activated by the C-terminal fragment of NPY, NPY(3–36). It inhibits adenylyl cyclase via Gαi/o signaling, reducing intracellular cAMP levels. NPY2R is highly expressed in the central nervous system, particularly in the hypothalamus, hippocampus, and brainstem, as well as in peripheral tissues like the gastrointestinal tract.
Recombinant NPY2R protein is produced using heterologous expression systems (e.g., mammalian, insect, or bacterial cells) to enable structural and functional studies. The protein is often engineered with tags (e.g., His-tag, FLAG) for purification and detection. Its recombinant form retains ligand-binding specificity and downstream signaling capabilities, making it valuable for investigating receptor-ligand interactions, signal transduction mechanisms, and drug screening.
Research on NPY2R has highlighted its role in obesity and metabolic disorders, as it modulates feeding behavior and energy expenditure. It is also implicated in anxiety, stress resilience, and gastrointestinal motility. Recombinant NPY2R facilitates the development of targeted therapies, such as agonists or antagonists, to treat conditions linked to NPY dysregulation. However, challenges remain in resolving its full 3D structure and optimizing ligand selectivity due to the complexity of GPCR dynamics.
In summary, NPY2R recombinant protein serves as a critical tool for advancing understanding of NPY-mediated pathways and accelerating therapeutic discovery for metabolic, neurological, and gastrointestinal diseases.
×
